摘要
多发性硬化 (MS)是神经学科的科研热点之一 ,至今虽无特效治疗 ,但多种新的有效治疗药物在临床和科研方面均取得了丰硕成果。本文综述了各型干扰素 (IFN)在多发性硬化病程中的作用机制 ,尤其是IFN - β对MS的治疗作用。并较完整的介绍了三种上市IFN制剂 (Betaseron、Avonex/Rebif和Roferon)的具体临床应用。
出处
《齐齐哈尔医学院学报》
2001年第8期954-956,共3页
Journal of Qiqihar Medical University
参考文献19
-
1[1]Isaacs A, Lindemann J. Virus interference. I. The interferon [J].Proc R Soc Lond(Bio), 1957,147:258 - 267
-
2[2]Neighbour PA, Miller AE,Bloom BR. Interferon responses of leukocytes in multiple sclerosis[J]. Neurology, 1981,31:561 - 566
-
3[3]Knobler RL, Panitch HS, Braheny SI, et al. Systemic alpha - interferon therapy of multiple sclerosis[J]. Neurology, 1984,34:1 273 -1 279
-
4[4]Jacbos L, O' Malley J, Freeman A, Ekes R. Intrathecally administered natural human fibroblast interferon reduced exacerbation of multiple sclerosis:results of a multi- center double blind study[J].Arch Neurol, 1987,44: 589 - 595
-
5[5]Camenga DL,Johnson KP, Alter M,et al. Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis[J]. Arch neurol, 1986,43:1 239- 1 246
-
6[6]Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbation associated with activation of the immune system [J]. Neurology, 1987,37:1 097- 1 102
-
7[7]Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon - β treatment of relapsing - remitting multiple sclerosis: pilot study analysis and six year fellow- up[J]. J Interferon Res, 1993,13: 333 - 340
-
8[8]The IFNB multiple Sclerosis Study Group. Interferon beta- 1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double - blind, placebo - controlled trial[J]. Neurology, 1993,43: 655 - 661
-
9[9]Paly DW,Li DKB, the UBC MS/MRI Study Group. Interferon beta - 1b is effective in relapsing remitting multiple sclerosis. Ⅱ . MRI analysis results of a multicenter, randomized, double- blind, placebo- controlled trial[J]. Neurology, 1993,43: 662 - 667
-
10[10]The IFNB multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta - 1b in the treatment of multiple sclerosis:final outcome of the randomized controlled trial[J]. Neurology, 1995,45:1 277- 1 285
同被引文献3
-
1谢琰臣,张华,许贤豪.干扰素-β治疗多发性硬化[J].中国神经免疫学和神经病学杂志,2006,13(2):124-127. 被引量：10
-
2McDonald WI, Compston A, Edan G,et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis[J]. Ann Neurol, 2001,50:121-127
-
3Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy andmanagement[J]. Neurology, 1999,53 (8):1 622-1 627
-
1Arnas.,B,金丽日.有关干扰素治疗多发性硬化的13个最常见问题[J].世界医学杂志,2000,4(7):26-30.
-
2多发性硬化症的早期干扰素治疗[J].国际医药卫生导报,2001,7(08B):32-32.
-
3乔文荣,梁英武.干扰素治疗格林巴利综合征疗效观察[J].济宁医学院学报,2000,23(4):48-49.
-
4曹莹.干扰素治疗儿童多动症的临床分析[J].内蒙古中医药,2010,29(6):94-95.
-
5景新.加拿大警告β干扰素有肝脏损伤[J].国外药讯,2004(4):40-40.
-
6Vogels MTE,蒋玖.免疫调节剂在细菌感染非特效治疗中的应用[J].国外医学（预防．诊断．治疗用生物制品分册）,1993,16(2):61-63.
-
7Avonex在美国的说明书被修改[J].天津药学,2003,15(3):86-86.
-
8张社峰,张民旺,王沛人.平痫颗粒治疗癫痫36例[J].中医研究,2009,22(3):38-40. 被引量：1
-
9钟敏.多发性硬化干扰素治疗的概况及进展[J].广东医学,2003,24(2):208-209.
-
10叶鸣.临床药学服务在新型抗癌剂的应用[J].临床合理用药杂志,2015,8(31):176-177.
